Preventing Functional Iron Deficiency in High-Risk Populations

Abstract

Functional iron deficiency (FID) presents a significant challenge in the management of high-risk populations, including patients with chronic kidney disease, heart failure, inflammatory disorders, and those receiving erythropoiesis-stimulating agents. Unlike absolute iron deficiency, FID is characterized by adequate or increased body iron stores with insufficient bioavailability for erythropoiesis due to impaired mobilization. This review synthesizes the latest evidence on epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic criteria, and treatment strategies, emphasizing the importance of early detection and targeted interventions for effective prevention. Recent advances in therapeutic options and current guideline recommendations are discussed to provide clinicians with a comprehensive framework for optimizing care in vulnerable populations.

Introduction

Iron homeostasis is essential for numerous physiological functions, most notably oxygen transport and cellular metabolism. Functional iron deficiency (FID) arises when iron stores are adequate but the supply to erythroid progenitors is limited, frequently resulting in suboptimal erythropoiesis. High-risk groups, such as individuals with chronic inflammatory diseases, chronic kidney disease (CKD), and those undergoing frequent phlebotomy or erythropoietin therapy, are particularly vulnerable. Preventing FID in these populations is crucial for maintaining hemoglobin levels, optimizing quality of life, and reducing morbidity. This review provides a structured synthesis of recent research, relevant clinical guidelines, and practical recommendations for preventing FID in high-risk cohorts.

Epidemiology / Disease Burden

Functional iron deficiency is prevalent across several high-risk populations. In CKD, up to 50% of patients exhibit FID, especially among those receiving hemodialysis. Similarly, FID is observed in approximately 40% of chronic heart failure patients and is highly prevalent among individuals with chronic inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis. The disease burden is significant, with FID contributing to increased hospitalization rates, reduced exercise tolerance, impaired cognitive function, and overall diminished quality of life. The economic impact is substantial, with increased healthcare utilization and treatment costs, particularly in chronic disease management.

Pathophysiology

FID is primarily driven by disturbances in iron metabolism pathways. Chronic inflammation induces hepatic synthesis of hepcidin, a key regulator that inhibits intestinal iron absorption and traps iron within macrophages and hepatocytes by blocking ferroportin. This results in reduced circulating iron despite sufficient or elevated ferritin stores. In CKD, decreased renal clearance further exacerbates hepcidin accumulation. Erythropoiesis-stimulating agents (ESAs), frequently used in anemia management, increase iron demand, compounding the risk of FID. The interplay between inflammatory cytokines, hepcidin, and iron transport mechanisms underpins the pathophysiology of FID, differentiating it from absolute iron deficiency.

Risk Factors

Recognizing risk factors is pivotal for early prevention. High-risk groups encompass individuals with chronic inflammatory conditions (e.g., CKD, heart failure, IBD, rheumatoid arthritis), frequent blood loss (gastrointestinal bleeding, menstrual losses), inadequate dietary intake, and those on long-term ESA therapy. Additional contributors include advanced age, malignancies, bariatric surgery, and genetic disorders affecting iron metabolism. Polypharmacy, especially the use of proton pump inhibitors or antacids, can impair iron absorption and exacerbate FID. Identifying and addressing modifiable risk factors is integral to preventive strategies.

Clinical Features

The clinical presentation of FID often mirrors that of absolute iron deficiency but may be more insidious. Symptoms include fatigue, pallor, exertional dyspnea, cognitive impairment, and reduced exercise tolerance. In patients with chronic diseases, these symptoms are frequently attributed to the underlying condition, leading to underdiagnosis. Laboratory findings typically reveal normocytic or microcytic anemia, low transferrin saturation (TSAT), and normal or elevated ferritin levels. Recognition of these subtle clinical and laboratory features is essential for timely intervention in high-risk populations.

Diagnosis

Diagnosis of FID relies on a combination of clinical suspicion and targeted laboratory assessment. Key parameters include serum ferritin, TSAT, serum iron, total iron-binding capacity (TIBC), and inflammatory markers such as C-reactive protein (CRP). In FID, ferritin is typically normal or elevated (>100 ng/mL), but TSAT is reduced (<20%). Newer biomarkers, such as soluble transferrin receptor (sTfR) and hepcidin assays, offer improved specificity, particularly in distinguishing FID from absolute iron deficiency in inflammatory states. Accurate diagnosis is crucial for guiding appropriate therapy and avoiding unnecessary iron supplementation in non-deficient patients.

Treatment & Management

Preventive and therapeutic strategies for FID focus on optimizing iron bioavailability and addressing underlying causes. Oral iron supplementation may be insufficient in the presence of elevated hepcidin levels or gastrointestinal intolerance; hence, intravenous iron preparations are often preferred in high-risk individuals, especially those with CKD or ongoing inflammation. ESA therapy should be carefully titrated to avoid excessive iron demand. Addressing modifiable risk factors, such as minimizing blood loss, optimizing dietary intake, and managing contributing medications, is vital. Individualized care plans, regular monitoring of iron indices, and patient education are essential components of effective management.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in the management of FID. Novel intravenous iron formulations, such as ferric carboxymaltose and ferric derisomaltose, offer improved safety profiles and enable larger, less frequent dosing. Hepcidin antagonists and agents targeting the inflammatory cascade are under investigation, aiming to restore iron homeostasis by modulating the underlying pathogenic mechanisms. Emerging evidence supports the integration of ferric citrate and other phosphate binders with iron-releasing properties in CKD management. These innovations hold promise for more effective prevention and treatment of FID in high-risk populations.

Guideline Recommendations

Major clinical guidelines, including those from KDIGO, European Society of Cardiology, and British Society of Gastroenterology, emphasize routine screening for iron deficiency in high-risk groups. Regular assessment of ferritin and TSAT is recommended, with intravenous iron supplementation preferred in the context of inflammation or poor oral tolerance. Guidelines endorse a multidisciplinary approach, involving nephrologists, cardiologists, hematologists, and dietitians, to ensure comprehensive care. Adherence to evidence-based protocols is associated with improved patient outcomes and reduced healthcare burden.

Conclusion

Prevention of functional iron deficiency in high-risk populations is a dynamic and multifaceted challenge. Clinicians must maintain vigilance for at-risk individuals, employ judicious diagnostic evaluation, and implement evidence-based interventions tailored to the underlying pathophysiology. Recent advances in iron therapy and a growing understanding of hepcidin biology offer new opportunities for optimizing patient care. Ongoing research and adherence to guideline-driven practice remain pivotal in reducing the burden of FID and enhancing the quality of life for vulnerable patient populations.